BUB1 and neoplasm: Previous research has confirmed that BUB1 could be viewed as a clinical biomarker for adverse prognosis and a potential therapeutic target in various tumours,15, 16 including aggressive colorectal cancer,17 breast cancer18 and glioblastoma.19